If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOvoca Bio Regulatory News (OVB)

  • There is currently no data for OVB

Half Yearly Report

30 Sep 2014 07:00

RNS Number : 9271S
Ovoca Gold PLC
30 September 2014
 

Ovoca Gold plc ("Ovoca" or the "Company")

 

2014 Interim Results

 

Ovoca is pleased to announce its interim financial statements and report covering the six month period from 1 January 2014 to 30 June 2014.

 

Please click on the following link to view thefull Half Year Report:

 

http://www.rns-pdf.londonstockexchange.com/rns/9271S_1-2014-9-29.pdf

 

 

Highlights:

· Cash and cash equivalents and available for sale financial assets of US$28.0 million as at 30 June 2014. 

· Total comprehensive profit for the six month period to 30 June 2014 of US$0.1 million. 

· Total finance income in the period amounted to approximately US$0.5 million, relating to our holding of Polymetal International plc shares and accrued interest.

 

 

Post period events:

· On 24 September 2014, the Board of Ovoca announced that it is seeking to put in place the necessary shareholder authorities to repurchase up to 20 per cent. of the Company's issued share capital by way of on-market share purchases. 

· On the same date, Ovoca also announced that it intends to seek approval from independent shareholders to satisfy Ovoca's obligations in relation to the payment of deferred consideration relating to the acquisition of the Stakhanovsky Licence, by way of a final payment by Ovoca of US$3 million. Ovoca now intends to seek a joint venture partner to develop the Stakhanovsky Licence or to potentially sell the Company's interest in the Licence.

 

 

CEO's Letter

 

Dear shareholders,

 

It is my pleasure to report to you our financials and the results of our work for the first half of 2014.

 

In 2014 the Company decided to widen its focus in exploration projects and started to search for new projects in the oil and gas resource sector in Russia. Since that time we have reviewed a number different investment opportunities but, due to the unstable geopolitical and market situation, we decided to refrain from any further immediate investments in our existing portfolio of projects as well as investments in new projects.

 

Although our financial position remains strong, after taking into account the continued volatility in the gold markets and the risks associated with the development of the mining operations on the Stakhanovsky Licence which would require additional capital investment from the Company and the fulfilment of certain obligations under the terms of the Stakhanovsky Licence, the Company has suspended exploration activities on the Stakhanovsky Licenced Area and intends to seek a joint venture partner to develop the Stakhanovsky Licence or to potentially sell the Company's interest in the Stakhanovsky Licence.

 

We look forward to the improvement of the geopolitical situation in Russia and we continue to believe in our ability to create value in unstable market conditions. The Company continues to search for new projects which could open new opportunities for the Company and its shareholders.

 

Kind regards,

 

Kirill Golovanov, CEO

 

ENDS

 

 

Enquiries:

 

Ovoca Gold Plc

Kirill Golovanov, CEO

 +7 495 916 6029

 

Davy - NOMAD, ESM Adviser and Broker

John Frain / Daragh O'Reilly +353 1 679 6363

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR QKCDNOBKDCCB
Date   Source Headline
29th Jul 20227:00 amRNSCompletion of Enrollment in Phase II Study
30th Jun 20227:00 amRNSAnnual Financial Report
7th Mar 20229:00 amRNSStatement re Russian Business Operations
23rd Feb 20224:41 pmRNSSecond Price Monitoring Extn
23rd Feb 20224:36 pmRNSPrice Monitoring Extension
22nd Feb 20223:30 pmRNSRussian Marketing Authorisation for Orenetide
31st Jan 20227:00 amRNSBoard Changes and Update
30th Dec 20217:00 amRNSDirectorate Change
4th Nov 20213:53 pmRNSHolding(s) in Company
4th Nov 20213:50 pmRNSDirector/PDMR Shareholding
4th Nov 20213:46 pmRNSBoard Change
14th Sep 20217:00 amRNSInterim Results
29th Jul 20215:00 pmRNSResult of AGM
24th Jun 20217:00 amRNSAnnual Report and Notice of AGM
10th Mar 20217:00 amRNSMigration of Participating Securities
16th Feb 20212:00 pmRNSResult of EGM
29th Jan 20217:00 amRNSFirst Patient Enrolled in Phase II Study - BP-101
25th Jan 20213:30 pmRNSNotice of EGM
5th Jan 20217:00 amRNSRe-Filing of Marketing Authorisation Application
17th Dec 20202:45 pmRNSResult of AGM
27th Nov 20203:08 pmRNSNotice of AGM
9th Oct 20207:00 amRNSAppointment of Chief Business Officer
2nd Oct 202011:06 amRNSSecond Price Monitoring Extn
2nd Oct 202011:00 amRNSPrice Monitoring Extension
2nd Oct 20209:05 amRNSSecond Price Monitoring Extn
2nd Oct 20209:00 amRNSPrice Monitoring Extension
2nd Oct 20207:00 amRNSUpdate re Russian Marketing Authorisation
28th Sep 20207:00 amRNSDeath of a Director
21st Sep 20207:00 amRNSInterim Results
14th Aug 202011:05 amRNSSecond Price Monitoring Extn
14th Aug 202011:00 amRNSPrice Monitoring Extension
26th Jun 20207:00 amRNSAnnual Report
14th Apr 20202:05 pmRNSSecond Price Monitoring Extn
14th Apr 20202:00 pmRNSPrice Monitoring Extension
24th Mar 20207:00 amRNSAcquisition of Remaining Minority Interest in IVIX
7th Nov 201912:45 pmRNSAttendance at Bio-Europe Conference
16th Sep 20197:00 amRNSInterim Results
12th Sep 20197:00 amRNSFiling of Marketing Authorisation Application
28th Aug 20197:00 amRNSDirectorate Change
8th Aug 20194:14 pmRNSResult of AGM
8th Aug 20199:05 amRNSSecond Price Monitoring Extn
8th Aug 20199:00 amRNSPrice Monitoring Extension
8th Aug 20197:00 amRNSAGM Statement
26th Jul 20197:00 amRNSDirectorate Change
25th Jul 20194:41 pmRNSSecond Price Monitoring Extn
25th Jul 20194:35 pmRNSPrice Monitoring Extension
28th Jun 20197:00 amRNSAnnual Report and Notice of AGM
23rd Apr 20197:00 amRNSUS and EU Clinical Development Plans
29th Mar 20197:00 amRNSDirector/PDMR Shareholding
27th Mar 20197:00 amRNSOperational Update & Additional Investment in IVIX

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.